Drug Profile

Research programme: acetylcholinesterase - Protalix Biotherapeutics

Alternative Names: AChE programme - Protalix Biotherapeutics

Latest Information Update: 12 Mar 2012

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boyce Thompson Institute for Plant Research; Hebrew University of Jerusalem
Developer Protalix Biotherapeutics
Class Antitoxins; Recombinant proteins
Mechanism of Action Cholinesterase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

07 Mar 2012 No development reported - Preclinical for Poisoning in Israel (Parenteral)
22 Jan 2008 Protalix Biotherapeutics extends its research agreement with Yissum Research Development Company to include a collaborative research programme at the Hebrew University of Jerusalem
22 Jan 2008 Preclinical trials in Poisoning in Israel (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com